Biotech r&d spending continues to rise

You have full access to this article via your institution. Download PDF Biotech R&D spending hit US$45.7 billion in 2016, up 12% from 2015, found an annual analysis of the sector by

consulting firm EY (see Fig. 1). This was the seventh consecutive year that these firms increased their cumulative R&D spending, and the second consecutive year in which R&D spending

growth outpaced revenue growth (7%). US firms poured the most new money into R&D, increasing their investment in science by 14%. European firms spent only an extra 3% on R&D in

2016. “The biotech industry's financial commitment to R&D, while impressive, needs to be coupled with efficiency improvements to achieve better returns and ultimately to drive

greater affordability of its products,” said Pamela Spence, EY Global Life Sciences Leader. “With pricing pressures expected to escalate, firms will need to incorporate new digital and

artificial intelligence technologies into their traditional drug target selection and overall R&D processes to achieve those returns or risk being outdone by firms that do.” Authors *

Asher Mullard View author publications You can also search for this author inPubMed Google Scholar POWERPOINT SLIDES POWERPOINT SLIDE FOR FIG. 1 RIGHTS AND PERMISSIONS Reprints and

permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Mullard, A. Biotech R&D spending continues to rise. _Nat Rev Drug Discov_ 16, 447 (2017). https://doi.org/10.1038/nrd.2017.130 Download

citation * Published: 29 June 2017 * Issue Date: July 2017 * DOI: https://doi.org/10.1038/nrd.2017.130 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this

content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative